PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12505434-3	2003	Our data show associations between non-workplace Cd exposure and changes in the abundance of hepatic and renal cortical CYP4A11.	Cadmium	49-51	cytochrome P450 family 4 subfamily A member 11	Homo sapiens	120-127	
17405690-12	2007	Renal cadmium reduces CYP4A11 and PPARs, which may be related to hypertension, sodium retention, glucose intolerance, dyslipidemia, and zinc deficiency.	Cadmium	6-13	cytochrome P450 family 4 subfamily A member 11	Homo sapiens	22-29	
12505434-6	2003	These observations suggest the potential for involvement of Cd as a mediator of CYP4A11 expression in kidney cortex and indicate that elevations in kidney Cd content may be involved in hypertension via alteration of the expression of this particular isoform.	Cadmium	60-62	cytochrome P450 family 4 subfamily A member 11	Homo sapiens	80-87	
12505434-4	2003	In liver the levels of immunochemically detectable CYP4A11 were positively correlated with tissue Cd content while in contrast CYP4A11 abundance was inversely correlated with kidney Cd burden.	Cadmium	98-100	cytochrome P450 family 4 subfamily A member 11	Homo sapiens	51-58	
12505434-7	2003	Potential mechanisms by which Cd may alter CYP4A11 expression are discussed briefly.	Cadmium	30-32	cytochrome P450 family 4 subfamily A member 11	Homo sapiens	43-50	
12505434-4	2003	In liver the levels of immunochemically detectable CYP4A11 were positively correlated with tissue Cd content while in contrast CYP4A11 abundance was inversely correlated with kidney Cd burden.	Cadmium	182-184	cytochrome P450 family 4 subfamily A member 11	Homo sapiens	127-134	
11992637-0	2002	Associations between human liver and kidney cadmium content and immunochemically detected CYP4A11 apoprotein.	Cadmium	44-51	cytochrome P450 family 4 subfamily A member 11	Homo sapiens	90-97	
11992637-1	2002	This present study was undertaken to assess potential effects of cadmium on CYP4A11 apoprotein in human liver and kidney as detected by Western blotting using a highly specific anti-peptide antibody.	Cadmium	65-72	cytochrome P450 family 4 subfamily A member 11	Homo sapiens	76-83	
11992637-5	2002	In contrast, increased CYP4A11 apoprotein levels were found in liver samples having higher cadmium content compared to the lower cadmium content samples.	Cadmium	91-98	cytochrome P450 family 4 subfamily A member 11	Homo sapiens	23-30	
11992637-5	2002	In contrast, increased CYP4A11 apoprotein levels were found in liver samples having higher cadmium content compared to the lower cadmium content samples.	Cadmium	129-136	cytochrome P450 family 4 subfamily A member 11	Homo sapiens	23-30	
11992637-6	2002	Increased CYP4A11 levels were also found in liver samples from female donors, compared to male donors; the difference being attributable to higher female liver cadmium burden.	Cadmium	160-167	cytochrome P450 family 4 subfamily A member 11	Homo sapiens	10-17	
11992637-7	2002	In distinction to liver, lowered CYP4A11 levels were seen in the kidney cortex samples which have high cadmium content.	Cadmium	103-110	cytochrome P450 family 4 subfamily A member 11	Homo sapiens	33-40	
11992637-8	2002	It is proposed here that the difference between the absolute cadmium burden of the liver and kidney samples may be responsible for the different patterns of expression of CYP4A11 in these two tissues.	Cadmium	61-68	cytochrome P450 family 4 subfamily A member 11	Homo sapiens	171-178	
11992637-9	2002	Further, since cadmium exposure may be associated with derangement in blood pressure control, it is interesting to note the possible relationship between altered CYP4A11-dependent production of arachidonic acid hydroxy and epoxy metabolites in kidney cortex and altered control of blood pressure.	Cadmium	15-22	cytochrome P450 family 4 subfamily A member 11	Homo sapiens	162-169